THC vs CBD: Understanding the Difference for Medical Patients

For patients newly entering the UK medical cannabis system, understanding the difference between THC and CBD is fundamental to making sense of your prescription options. While both are cannabinoids derived from the cannabis plant, they act through different biological mechanisms, produce different effects and are suited to different medical conditions and patient profiles.

How THC Works: CB1 Receptors and Psychoactive Effects

Delta-9-tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis. It works primarily by binding to CB1 receptors — the most abundant G-protein-coupled receptors in the human brain — in areas including the prefrontal cortex, hippocampus, basal ganglia and cerebellum. This binding inhibits the release of various neurotransmitters, producing effects that include analgesia, muscle relaxation, appetite stimulation, reduction in nausea and, at higher doses, psychoactive effects including euphoria, altered time perception and short-term memory impairment.

In a medical context, THC's analgesic and anti-nausea properties are most relevant. It is the primary active compound for conditions including neuropathic pain, chemotherapy-induced nausea, spasticity in multiple sclerosis and appetite loss associated with HIV or cancer. The psychoactive effect is considered a side effect in medical use, and clinical prescribing aims to achieve therapeutic benefit at the lowest effective dose.

At higher doses, particularly in patients who are naive to cannabis, THC can induce anxiety, paranoia and, in rare cases, acute psychotic symptoms. This is why UK clinicians start prescriptions at very low doses and titrate slowly. Patients with a personal or family history of psychosis are generally not prescribed high-THC products. UK licensed clinics screen all patients for these risk factors before prescribing.

How CBD Works: CB2, TRPV1 and Non-Psychoactive Benefits

Cannabidiol (CBD) acts through a fundamentally different pharmacological profile. It has low affinity for CB1 receptors and does not produce intoxication at any clinically relevant dose. Instead, CBD exerts its effects primarily through:

• CB2 receptors: Expressed mainly on immune cells and peripheral tissues, CB2 activation produces anti-inflammatory effects relevant for conditions including rheumatoid arthritis, inflammatory bowel disease and some neuropathic conditions.
• TRPV1 (vanilloid) receptors: CBD activates TRPV1 channels, which are involved in pain and temperature sensation, contributing to its analgesic and anti-inflammatory actions.
• Serotonin receptors (5-HT1A): At higher doses, CBD acts as an agonist at 5-HT1A receptors, producing anxiolytic effects. This is thought to underlie its efficacy in anxiety disorders and PTSD.
• GPR55 receptor: CBD's antagonism of GPR55 may contribute to its anti-epileptic properties, relevant to its licensed use in Dravet syndrome and Lennox-Gastaut syndrome via Epidyolex.

CBD has a favourable side effect profile at medical doses: the most common adverse effects are fatigue, diarrhoea and changes in appetite. It does not impair driving or cognitive function at recommended doses. You can compare prices on CBD-dominant and full-spectrum products available through UK pharmacies.

Ratio Products and Which Conditions Suit THC vs CBD

In UK clinical practice, prescriptions are rarely for pure THC or pure CBD. Most products contain a ratio of the two cannabinoids, and understanding these ratios is key to matching the medicine to the condition.

High-THC products such as 20:1 THC:CBD ratios are used for severe neuropathic pain, advanced cancer pain, chemotherapy-induced nausea and profound sleep disturbance. These are typically prescribed for evening or night-time use.

Balanced 1:1 products are a common starting point for chronic pain, anxiety disorders and PTSD. The CBD attenuates THC's psychoactive effect, producing a more functional, less intoxicating experience while retaining analgesic and anxiolytic benefit.

High-CBD products such as 1:20 THC:CBD ratios are preferred for anxiety, inflammatory conditions, certain epilepsy syndromes and patients who cannot tolerate any psychoactive effect. CBD-dominant oils are also used as add-on daytime therapy when a patient is already taking a THC-containing product at night.

Your prescribing specialist will recommend the appropriate ratio based on your condition, symptom profile and prior experience with cannabis. Explore qualifying conditions to see which cannabinoid profile is most commonly associated with your diagnosis.

Drug Interactions and Practical Considerations for UK Patients

Both THC and CBD interact with the cytochrome P450 enzyme system in the liver, which metabolises the majority of commonly prescribed medicines. CBD in particular is a potent inhibitor of CYP3A4 and CYP2C19, meaning it can increase the plasma concentration of drugs including warfarin, clobazam, some statins, certain antidepressants and immunosuppressants. Patients taking these medicines should inform their prescribing clinician before starting any CBPM, as dose adjustments may be required.

THC can potentiate the sedative effects of alcohol, benzodiazepines, opioids and antihistamines, and patients combining these substances should exercise particular caution. Conversely, THC may reduce the effectiveness of some antidepressants in a small proportion of patients. These interactions are manageable with appropriate clinical monitoring but highlight the importance of full medication disclosure at your initial consultation.

From a practical standpoint, UK patients should be aware that driving while impaired by THC is a criminal offence under the Road Traffic Act 1988, and there is a specific legal threshold for THC in blood. The fact that cannabis has been legally prescribed does not exempt patients from this limit. CBD-only products that contain zero THC do not impair driving and carry no legal risk in this context. Your prescribing clinician can advise on appropriate timing of doses relative to driving, particularly during the titration phase when individual sensitivity is being established.